S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
Positive News SentimentPositive News
NASDAQ:PRVB

Provention Bio (PRVB) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$24.98
▼
$25.00
50-Day Range
$23.74
▼
$24.98
52-Week Range
$3.18
▼
$25.00
Volume
9.12 million shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.83
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Provention Bio MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
8.6% Downside
$22.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.52
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.72) to ($0.42) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

935th out of 969 stocks

Pharmaceutical Preparations Industry

439th out of 453 stocks

See Top Rated MarketRank™ Stocks Here

PRVB stock logo

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.


PRVB Stock News Headlines

May 1, 2023 | finance.yahoo.com
Sanofi/Provention: innovative diabetes drug is a good fit
April 29, 2023 | finance.yahoo.com
Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%
October 2, 2023 | Legacy Research (Ad)
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
April 28, 2023 | seekingalpha.com
Sanofi completes Provention Bio acquisition
April 27, 2023 | finance.yahoo.com
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline
April 27, 2023 | finanznachrichten.de
Sanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
April 26, 2023 | seekingalpha.com
Provention Bio gains after HSR waiting period for Sanofi deal expired
April 26, 2023 | benzinga.com
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
October 2, 2023 | Legacy Research (Ad)
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
April 22, 2023 | finance.yahoo.com
PRVB Apr 2023 23.000 put
April 11, 2023 | msn.com
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
April 2, 2023 | finance.yahoo.com
Provention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimates
March 27, 2023 | bizjournals.com
Gaithersburg’s Novavax locks in consulting deal with outgoing R&D head
March 17, 2023 | benzinga.com
(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?
March 16, 2023 | finance.yahoo.com
Q4 2022 MacroGenics Inc Earnings Call
March 15, 2023 | benzinga.com
Provention Bio's Earnings Outlook
March 14, 2023 | msn.com
SMBC Nikko Downgrades Provention Bio (PRVB)
March 14, 2023 | msn.com
Jefferies Downgrades Provention Bio (PRVB)
March 14, 2023 | proactiveinvestors.com
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
March 14, 2023 | benzinga.com
Short Volatility Alert: Provention Bio Inc
March 14, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About Provention Bio
March 13, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi
March 13, 2023 | finance.yahoo.com
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
March 13, 2023 | msn.com
Sanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drug
March 13, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Provention Bio, Inc. Buyout
March 13, 2023 | businesswire.com
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders
March 13, 2023 | investorplace.com
Why Is Provention Bio (PRVB) Stock Up 263% Today?
See More Headlines
Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings
11/04/2021
Today
10/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
CUSIP
N/A
CIK
1695357
Web
www.proventionbio.com
Phone
(908) 428-9136
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.83
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
-8.6%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,570,000.00
Net Margins
-880.69%
Pretax Margin
-984.54%
Return on Equity
-103.36%
Return on Assets
-69.08%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
1.93
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$12.90 million
Price / Sales
183.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
17.84

Miscellaneous

Outstanding Shares
94,780,000
Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Ashleigh W. PalmerAshleigh W. Palmer
    Chief Executive Officer & Director
  • Christina Yi
    Chief Operating Officer
  • Thierry Chauche
    Chief Financial Officer
  • Francisco LeonFrancisco Leon
    Chief Scientific Officer
  • Eleanor Leni Ramos
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRVB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRVB, but not buy additional shares or sell existing shares.
View PRVB analyst ratings or view top-rated stocks.

What is Provention Bio's stock price forecast for 2023?

7 Wall Street analysts have issued 12-month target prices for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $25.00. On average, they expect the company's stock price to reach $22.83 in the next year. This suggests that the stock has a possible downside of 8.6%.
View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) announced its earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company earned $0.68 million during the quarter, compared to analysts' expectations of $3.75 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%. During the same quarter last year, the business posted ($0.56) EPS.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $24.98.

How much money does Provention Bio make?

Provention Bio (NASDAQ:PRVB) has a market capitalization of $2.37 billion and generates $12.90 million in revenue each year. The company earns $-113,570,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -